a, Immunoblot of WCL from peripheral blood primary human B-cells
that were resting or that were stimulated by Mega-CD40L (50 ng/ml), anti-IgM
(1 μg/ml), CpG (0.5 μM), IgM+ CpG or CD40 + CpG for 24
hours.
b, Normalized DNMT3B, DNMT3A, DNMT1 or UHRF1 mRNA levels in primary
human peripheral blood B-cells at the indicated day post infection (DPI) by
the EBV B95.8 strain32. Shown are the mean + SEM values from n=3 of
biologically independent RNAseq datasets.
c, UHRF1, DNMT1, DNMT3A and TET2 relative protein abundances
detected by tandem-mass-tag-based proteomics at rest and at nine time points
after EBV B95.8 infection of primary human peripheral blood B-cells at a
multiplicity of infection of 0.1. DNMT3B expression was not detected. Data
represent the average +/− SEM for four independent replicates8. For
each protein, the maximum level detected across the time course was set to a
value of one.
d, Volcano plot visualization of -Log10 (p-value) statistical
significance (y-axis) and Log2 fold-change in mRNA abundance (x-axis) of ex
vivo GC B-cells that conditionally expressed control GFP or both LMP1 and
LMP2A from an AICDA promoter, which is activated in GC B-cells. Data are
from n=3 of biologically independent RNA-seq datasets34. P-value and log
fold change were generated with DESeq under default settings with Wald test
and Normal shrinkage, respectively. UHRF1, DNMT1, DNMT3A and DNMT3B values
are highlighted.
e, Normalized EBNA1 mRNA reads from RNAseq analysis of MUTU I (n=3)
or Rael cells (n=2) that expressed control or UHRF1 sgRNAs, as indicated.
p-values were calculated by unpaired two-sided student’s t-test with
equal variance assumption.
f, Immunoblot analysis of WCL from MUTU III or from MUTU I that
expressed the indicated control or UHRF1 sgRNAs. Cells were harvested at the
indicated day post sgRNA delivery by lentivirus transduction.
Blots in a and f are representative of n=3 biologically independent
replicates.